NKG2D

P7 graphical abstract


Project-related publications

P1, P3, P4, P6, P7, P8, INF

Myeloid cell–mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference

Lustig M, Kowol M, Hartmann AM, van der Peet IC, Jansen MJH, Iben K, Winterberg D, Krohn S, Baumann N, Rösner T, Bendig S, Hahn C, Wurm AA, Gehlert CL, Denker M, Suwanchaikasem P, Macarrón Palacios A, Schwartz S, Brüggemann M, Burger R, Schmitt K, Klausz K, Valerius O, Stölzel F, Bastian L, Baldus CD, Peipp M, Leusen JHW, Schewe DM, Valerius T.

Blood Neoplasia
2026
P1, P3, P4, P6, P7, Z

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL

Pinkle D, Cornils M, Dietterle A, Laqua A, Kurschies M, Heymann J, Funke E, Fanter P, Gupta DD, Reimer C, Mahachi DT, Gehlert CL, Winterberg D, Vossen-Gajcy M, Müller X, Balow G, Iben K, Barz M, Bastian L, Baldus C, Kowol M, Kikvadze S, Wurm AA, Logvinova E, Vokuhl C, Schmid JP, Jeremias I, Klausz K, Peipp M, Schrappe M, Baccelli I, Poirier N, Brüggemann M, Cario G, Schewe DM, Lenk L.

Hemasphere
2026
P1, P3, P6, P7, Z

The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL via antibody-dependent cellular phagocytosis

Lenk L, Baccelli I, Laqua A, Heymann J, Reimer C, Dietterle A, Winterberg D, Mary C, Corallo F, Taurelle J, Narbeburu E, Neyton SL, Déramé M, Pengam S, Vogiatzi F, Bornhauser B, Bourquin JP, Raffel S, Dovhan V, Schüler T, Escherich G, den Boer ML, Boer JM, Wessels W, Peipp M, Alten J, Antić Ž, Bergmann AK, Schrappe M, Cario G, Brüggemann M, Poirier N, Schewe DM.


Researchers

Prof. Dr. rer. nat. Matthias Peipp

Principal Investigator
Division of Antibody-based Immunotherapy / University Medical Center Schleswig-Holstein, Campus Kiel, Clinic for Internal Medicine II, Hematology and Oncology / University Medical Center Schleswig-Holstein, Campus Kiel
P7

Participating Institutes